Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Clinical Lecturer







455Norfolk PlaceSt Mary's Campus





I am Senior Clinical Research Fellow in vaccinology and Honorary Consultant in genitourinary medicine at Imperial College London and Imperial College Healthcare NHS Trust. I read medicine at Newnham College, University of Cambridge, and Imperial College London before completing speciality training as a clinician scientist in genitourinary medicine and immunology. My research investigates diversity in T cell responses to accelerate discovery in vaccine design and implementation. I lead first-in-human trials and experimental medicine studies of novel vaccines against hard-to-target pathogens including HIV and chlamydia. I am Chief and Principal Investigator for the Imperial College London self amplifying RNA SARS-CoV-2 vaccine and Oxford Astra-Zeneca COVID-19 vaccine trials. I received a Department of Infectious Disease award for substantial and exceptional achievement during the COVID-19 pandemic. 





Pollock KM, Cheeseman HM, Szubert AJ, et al., 2022, Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial, Eclinicalmedicine, Vol:44, ISSN:2589-5370, Pages:101262-101262

Cole ME, Guo Y, Cheeseman HM, et al., 2022, Multicolor Flow Cytometry and High-Dimensional Data Analysis to Probe Complex Questions in Vaccinology., Methods Mol Biol, Vol:2414, Pages:433-447

Hodgson SH, Iveson P, Larwood J, et al., 2021, Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial, Cts-clinical and Translational Science, ISSN:1752-8054

Feng S, Phillips DJ, White T, et al., 2021, Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection, Nature Medicine, Vol:27, ISSN:1078-8956, Pages:2032-2040

Flaxman A, Marchevsky NG, Jenkin D, et al., 2021, Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002), The Lancet, Vol:398, ISSN:0140-6736, Pages:981-990

More Publications